RxDoctor Payments Data

Luiza Guseynov, MD

Family Medicine · Bronx, NYNPI 1114994134

Payments from drug & device makers

$1,983in general payments, 2019–2025

Across 93 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$717
  • AbbVie$494
  • Exact Sciences$260
  • Amgen$114
  • Pfizer$69
  • GSK$60
  • plus $269 from 6 others

What the payments were for

  • Food & beverage$1,983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk32$717
AbbVie(2 entities)29$494
Exact Sciences9$260
Amgen(2 entities)5$114
Pfizer2$69
GSK3$60
Bayer2$55
AstraZeneca3$47
Novartis3$47
E.r. Squibb & Sons, L.L.C.2$46
Lilly USA, LLC2$44
Biohaven Pharmaceuticals, Inc.1$29

How this compares

$1,983 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$21,623
Medicare patients
64
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate201$187,374
JardianceEmpagliflozin171$181,128
OzempicSemaglutide109$100,486
EliquisApixaban112$94,848
VascepaIcosapent Ethyl201$71,199
TrulicityDulaglutide37$43,339
Breo ElliptaFluticasone/Vilanterol76$29,343
LinzessLinaclotide37$28,781
FarxigaDapagliflozin Propanediol33$25,971
XareltoRivaroxaban20$15,936
EntrestoSacubitril/Valsartan20$15,891
TradjentaLinagliptin22$13,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,801
NexiumEsomeprazole Magnesium21$7,644
Tresiba Flextouch U-200Insulin Degludec11$7,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$717$100,486109 claims
PfizerEliquis$69$94,848112 claims
Lilly USA, LLCTrulicity$44$43,33937 claims
GSKBreo Ellipta, Trelegy Ellipta$60$39,14491 claims
AstraZenecaFarxiga, Nexium$47$33,61454 claims
AbbVieLinzess$494$28,78137 claims
NovartisEntresto, Diovan$47$20,39531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →